The Filing Desk

Innoviva vs Travere Therapeutics

Innoviva INVA · Travere Therapeutics TVTX · Pharmaceuticals

Travere Therapeutics reported revenue of $491 million in fiscal 2025, 1.2 times Innoviva's $411 million in fiscal 2025. Innoviva's revenue grew 14.7% in its latest year, and Travere Therapeutics' grew 110.5%. Innoviva had an operating margin of 39.8%, against -12.8% at Travere Therapeutics.

Side by side

InnovivaTravere Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$411M$491M
Revenue growth14.7%110.5%
Revenue growth a year, last 5 years4.1%19.9%
Gross margin74.8%97.9%
Operating margin39.8%−12.8%
Net margin65.9%−5.2%
Free cash flow$196M—
Free cash flow margin47.6%—
Return on capital17.9%—
Net debt to EBITDA——
Dividends and buybacks$4M$0M
Change in diluted share count14.2%13.1%
Last close$19.03$50.65
P/E at the last close9.5×—
Insider trades, last 12 months—sold $95.9 million
Piotroski F-score6 of 97 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
InnovivaTravere Therapeutics
Operating margin
Percent of revenue
InnovivaTravere Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InnovivaTravere Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Innoviva and Travere Therapeutics pages.